Results for upper bound concentrations translation from English to Maltese

upper-bound concentrations are calculated assuming that all values of the different congeners less than the limit of determination are equal to the limit of determination.
konċentrazzjonijiet tas-saff ta' fuq jiġu kkalkolati billi wieħed jassumi li l-valuri kollha tad-diversi konġeneri anqas mill-limitu ta'l-identifikazzjoni huma daqs il-limitu ta'l-identifikazzjoni.

the sugammadex pharmacokinetic parameters were calculated from the total sum of non-complex- bound and complex-bound concentrations of sugammadex.
il-parametri farmakokinetiċi ta’ sugammadex kienu kkalkulati mis-somma totali ta’ konċentrazzjonijiet mhux marbutin-kumplessivamenti ta’ sugammadex u ta’ konċentrazzjonijiet marbutin-kumplessivament ta’ sugammadex.

the upper bound of one-sided 95% confidence interval (ci) for predicted effect on qtcf at cmax was 4.8 msec.
il-kurva ta’ fuq tal-intervall b’kunfidenza ta’ 95% (ci) unidirezzjonali għall-effett imbassar fuq qtcf at cmax kienet ta’ 4.8 msek.

compared with the december 2006 eurosystem staff projections, the upper bound of the range projected for inflation in 2007 is somewhat lower, largely reflecting the fall in oil prices.
meta jitqabblu mal-proġettazzjonijiet ta » l-istaff ta » l-eurosistema ta » diċembru 2006, l-ogħla parti ta » l-iskala pproġettata għall-inflazzjoni fl-2007 hi ftit iżjed baxxa, u dan jirrifletti l-iżjed it-tnaqqis fil-prezzijiet taż-żejt.

a pharmacokinetic analysis predicted a drug-related qtc interval prolongation at 80 mg of 14 msec with an upper bound of 16 msec (90% ci).
analiżi farmakokinetika bassret titwil fl-intervall qtc relatat mal-mediċina f'80 mg ta' 14 msec b'limitu massimu ta' 16 msec (90% ci).

as it is important that as many samples as possible be analysed, the maximum levels proposed are somewhat higher than normal background levels given that they constitute upper-bound levels.
peress li huwa importanti li jiġu analizzati kampjuni kemm jista' jkun, il-livelli massimi proposti huma kemxejn ogħla mill-livelli normali fl-ambjent minħabba li jikkostitwixxu livelli fis-saff ta' fuq.

ci = confidence interval, os = overall survival time, a '+ 'denotes that the upper bound limit had not been reached at cut-off
ci = intervall tal- kunfidenza, os = żmien totali ta ’ sopravivenza, is- sinjal ‘ + ’ juri li l- upper bound limit ma ntlaħaqx fil- cut- off.

in many member states neet rates are considerably above the lowest levels recorded since 2008 and still close to the upper bounds.
f’ħafna stati membri, ir-rati tan-neet huma konsiderevolment ’il fuq mil-livelli l-aktar baxxi reġistrati mill-2008 u xorta qrib tal-ogħla limiti.

(28) dose constraint means a constraint set as a prospective upper bound of an individual dose, used to define the range of options considered in the process of optimisation for a given radiation source in a planned exposure situation;
(28) "restrizzjoni fuq id-doża" tfisser restrizzjoni stabbilita bħala l-ogħla limitu prospettiv ta’ doża individwali, użata biex tiddefinixxi firxa ta' alternattivi ikkunsidrati fil-proċess tal-ottimizzazzjoni għal sors partikolari ta’ radjazzjoni f’sitwazzjoni ta’ esponiment ippjanat;

the sonidegib plasma concentration-qtc analysis showed that the upper bound of one-sided 95% confidence interval for qtc increase was below 5 msec at steady-state cmax for 800 mg daily doses, which provide
analiżi tal-qtc tal-konċentrazzjoni ta’ sonidegib fil-plażma wriet li kien hemm żieda fil-parti superjuri ta’ naħa minnhom tal-95% intervall ta’ kunfidenza tal-qtc ta’ anqas minn 5 msek fis-cmax fi stat wieqaf f’każ ta’ dożi ta’ 800 mg mogħtija kuljum, li jipprovdu espożizzjoni fil-plażma ta’

a concentration-qtc response analysis based on the data from study a demonstrated that at average steady-state concentrations the upper bound of the 2-sided 90% ci for qtc increase from baseline was 16 msec at zykadia 750 mg.
analiżi tar-rispons tal-qtc skont il-konċentrazzjoni msejsa fuq dejta minn studju a wriet li l-konċentrazzjonijiet medji waqt stat wieqaf fil-limitu superjuri taż-żewġ naħat tad-90% ci għaż- żieda ta’ qtc mil-linja bażi kienet ta’ 16-il msek b’750 mg zykadia.

fluenz tetra demonstrated immunologic non-inferiority to the two formulations of fluenz as the upper bound for each of the four 95% cis for the post-dose strain-specific gmt hai antibody ratios was ≤ 1.5.
fluenz tetra wera noninferjorità immunoloġika għaż-żewġ formulazzjonijiet ta’ fluenz għax l-upper bound għal kull wieħed mill-erba’ 95% cis għall-proporzjonijiet tal-antikorpi gmt hai speċifiċi għar-razza wara d-dożaġġ kien ta’ ≤ 1.5.

2, sept 2009) on the basis of an estimated upper bound of the 95% confidence interval for 0 events given the number of patients treated with efavirenz in these clinical trials (n=3,969).
2, sett 2009) fuq il-bażi ta’ stima tal-upper bound tal-intervall ta’ kunfidenza ta’ 95 % għal każijiet 0 meta jitqiesu n-numru ta’ individwi kkurati b’efavirenz f’dawn il-provi kliniċi (n=3,969).

a mean increase in individual corrected qt interval (qtci) of up to 6.7 ms (upper bound of 95% one-sided ci 12.6 ms) was observed within 3 hours of dosing.
Żieda medja fl-intervall qt ikkoreġut individwalment (qtci) sa 6.7 ms (upper bound ta’ 95% one-sided ci 12.6 ms) kienet osservata fi żmien 3 sigħat minn meta ngħatat id-doża.

at a mirabegron dose of 200 mg, the qtci interval did not exceed 10 msec at any time point in males, while in females the upper bound of the one-sided 95% confidence interval did exceed 10 msec between 0.5–6 hours, with a maximum difference from placebo at 5 hours where the mean effect was 10.42 msec (upper bound of the one-sided 95% ci 13.44 msec).
f‟doża ta‟ mirabegron 200 mg, l-intervall qtci ma qabiżx 10 msec fl-ebda ħin fl-irġiel, filwaqt li fin-nisa, il-limitu l-aktar għoli tal-intervall ta‟ kunfidenza ta‟ 95% b‟naħa waħda fil-fatt qabeż 10 msec bejn 0.5–6 sigħat, b‟differenza massima minn plaċebo ta‟ 5 sigħat fejn l-effett medju kien ta‟ 10.42 msec (il-limitu l-aktar għoli ta‟ ci ta‟ 95% b‟naħa waħda 13.44 msec).